USPTO serial 79091998
ACLARUSDX
Reviewed by CopyMark Law Group
Reg. 4024702Status 404
- Filing date
- Status date
- Registration date
- Sep 13, 2011
- Examiner
- FRYE, KIMBERLY
- Law office
- TMO LAW OFFICE 113
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ACLARUSDX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical preparations and compositions, namely, nucleic acids attached to a solid medium, for industrial and scientific use; chemical fissile preparations for laboratory use; chemical fissile preparations for scientific research; chemical preparations for nucleic acids attached to a solid medium, other than for medical or veterinary purposes; biological preparations, other than for medical or veterinary purposes, namely, blood for enabling the quantification of nucleic acid content; chemicals for scientific use, other than for medical or veterinary purposes; chemical preparations or reagents for laboratory, namely, nucleic acid to screen and analyze gene expression, to identify therapeutic targets and products, and to conduct pharmacogenomic and genotoxicity research in the fields of pharmacology, food, chemistry, cosmetology, plant protection, and veterinary sciences; chemical preparations for scientific use, namely, nucleic acid libraries to screen and analyze gene expression, to identify therapeutic targets and products, and to conduct pharmacogenomic and genotoxicity research in the fields of pharmacology, food, chemistry, cosmetology, plant protection, and veterinary sciences; chemical preparations for scientific use, namely, DNA biochips for decoding genes affected by the Alzheimer's disease or revealing the transcriptomic signature of patients affected with Alzheimer's disease, and DNA chips to make visible and analyze gene expression in the fields of human and pharmacological medicine and veterinary science | SECTION 7(e) - CANCELLED | — |
| 005 | Pharmaceutical preparations for treating neurodegenerative diseases, particularly Alzheimer's disease; diagnostic reagents and media for medical use, namely, reagents and media for use in testing blood biomarkers, to enable the identification of patients suffering from Alzheimer's disease or at risk of developing the disease and for enabling the identification of patients responding to specific treatments; acidic biological preparations and products for pharmaceutical purposes, namely, pharmaceutical preparations for diagnosing Alzheimer's disease; capsules for diagnostic tests and medicines sold empty; chemico-pharmaceutical preparations for diagnosing, preventing and treating Alzheimer's disease; biopharmaceutical preparations for diagnosing, preventing and treating Alzheimer's disease; chemicals for medical, pharmaceutical or veterinary purposes, namely, chemicals for diagnosing neurodegenerative diseases, especially Alzheimer's disease; medical and clinical diagnosis testing kits comprised of nucleic acid banks, nucleic acids on DNA chips and testing probes; DNA libraries and RNA libraries for medical diagnostic purposes; nucleic acid sequences for use on biochips, for medical and medical diagnostic use, namely, for decoding genes affected by Alzheimer's disease or revealing the transcriptomic signature of patients suffering from Alzheimer's disease; enzymes or enzyme preparations for medical or veterinary purposes, namely, enzyme stabilizers and enzyme substrates used as ingredients in medicines for treatment of Alzheimer's disease; reagents contained in diagnostic test kits for taking blood samples, for the preservation of the biological material under analysis in order to carry out the test under the appropriate conditions | SECTION 7(e) - CANCELLED | — |
| 010 | Surgical, medical, dental and veterinary apparatus and instruments, namely, apparatus and instruments for use in identifying, assessing the seriousness of, assessing the prognoses of, measuring the progression of and measuring the conversion of neurodegenerative diseases such as Alzheimer's; medical apparatus using DNA chips for analyzing blood; apparatus for analyzing blood; apparatus for medical diagnostic purposes, namely, kits for taking blood samples comprising medical instruments for taking blood, DNA chips for diagnosing Alzheimer's disease, and material required for the preservation of the biological material under analysis in order to carry out the test under the appropriate conditions; spoons for medicines; containers specially adapted for the application of medicines, namely, bags and pouches used in the delivery of medication; probes for medical purposes; syringes for medical purposes; galvanic therapeutic devices for diagnosing neurodegenerative diseases, especially Alzheimer's disease | SECTION 7(e) - CANCELLED | — |
| 042 | Research and development for others of pharmaceutical molecules or biological markers and medicines for diagnosing and treating neurodegenerative diseases; chemical analyses; chemical research; chemical services, namely, analysis of RNA genes, tissues, and blood samples; biotechnological project studies to identify people suffering from Alzheimer's disease and to measure the seriousness, prognoses, progression and conversion of the disease and to determine how patients respond to treatments; research and development of new products for others; biological research; biotechnological research; technical research in the field of biotechnology; biotechnological analysis services; laboratory analyses, namely, quantification of nucleic acid content for medical and scientific research purposes | SECTION 7(e) - CANCELLED | — |
| 044 | Medical services; veterinary services; medical assistance; consulting in the fields of biotechnology and pharmacy, namely, to assist in the selection of Alzheimer's sufferers for clinical trials and to offer personalized treatments; hospitals; pharmacist's services to make up prescriptions; pharmaceutical advice; medical services, namely, facilitating the diagnosis and care of geriatric patients and patients with neurodegenerative diseases; health care; telemedicine services | SECTION 7(e) - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ExonHit Therapeutics
- Other trademarks owned by ExonHit Therapeutics
- Other trademarks owned by EXONHIT S.A.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named ACLARUSDX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 10, 2021 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED | — |
| Sep 10, 2021 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Sep 25, 2015 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Sep 2, 2015 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Sep 2, 2015 | INPC | INVALIDATION PROCESSED | — |
| Aug 5, 2015 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Dec 5, 2014 | C7.. | CANCELLED SECTION 7-TOTAL | — |
| Dec 5, 2014 | CANT | CANCELLATION TERMINATED NO. 999999 | — |
| Dec 3, 2014 | CAND | CANCELLATION DENIED NO. 999999 | — |
| Oct 24, 2014 | PETC | CANCELLATION INSTITUTED NO. 999999 | — |
| May 19, 2013 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Dec 23, 2011 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Dec 23, 2011 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Dec 13, 2011 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 15, 2011 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Sep 13, 2011 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 28, 2011 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 28, 2011 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 26, 2011 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| May 26, 2011 | ALIE | ASSIGNED TO LIE | — |
| May 12, 2011 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 12, 2011 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 12, 2011 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 12, 2011 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 12, 2011 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 26, 2011 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 26, 2011 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 26, 2011 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 26, 2011 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 27, 2011 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 9, 2011 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 9, 2011 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 9, 2011 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 8, 2011 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 8, 2011 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 4, 2011 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 4, 2011 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 3, 2011 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |